David M. Aboulafia
Experienced in IgG4-Related Disease

Dr. David M. Aboulafia

Oncology | Hematology
CommonSpirit Health
Virginia Mason Medical Center
1100 Ninth Avenue, 
Seattle, WA 
Accepting New Patients
Offers Telehealth

Experienced in IgG4-Related Disease
CommonSpirit Health
Virginia Mason Medical Center
1100 Ninth Avenue, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Aboulafia, MD, has special interest in AIDS/HIV, viral syndromes, general hematology including coagulation and hemostasis, lympho and myeloproliferative disorder, leukemia, lymphoma, myeloma, primary and subspecialty, and HIV-associated malignancies, benign hematology including disorders of coagulation and thrombosis, HIV primary and subspecialty care AIDS defining (Kaposi's sarcoma, lymphoma) and HIV-associated cancer.

Dr. Aboulafia is rated as an Experienced provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Non-Hodgkin Lymphoma, Anal Cancer, Kaposi Sarcoma, B-Cell Lymphoma, and Splenectomy.

His clinical research consists of co-authoring 73 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Michigan Medical School, Ann Arbor - 1983
Residency
Internal Medicine, University of California, Los Angeles Medical Center - 1986
Specialties
Oncology
Hematology
Licenses
Internal Medicine in WA
Board Certifications
American Board Of Internal Medicine, Subspecialty In Medical Oncology, Subspecialty In Hematology, Subspecialty In HIV Clinical Care
Fellowships
Hematology and Oncology, University of California, Los Angeles Medical Center - 1989
Hospital Affiliations
Virginia Mason Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Lifewise

Accepted plan types not found. Please verify directly with the provider.

Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

Virginia Mason Medical Center
1100 Ninth Avenue, Seattle, WA 98101
Call: 206-624-1144

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


17 Clinical Trials

A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
Enrollment Status: Completed
Publish Date: December 17, 2025
Intervention Type: Other, Drug
Study Drug: Nelfinavir Mesylate
Study Phase: Phase 2
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: September 23, 2025
Intervention Type: Biological, Procedure
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Vinblastine
Study Phase: Phase 1/Phase 2
A Randomized, Phase III Study of Intra-anal Imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women
A Randomized, Phase III Study of Intra-anal Imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women
Enrollment Status: Completed
Publish Date: July 23, 2025
Intervention Type: Drug, Other
Study Drugs: Imiquimod, Fluorouracil
Study Phase: Phase 3
A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: July 18, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Pegfilgrastim, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 1
Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma
Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma
Enrollment Status: Terminated
Publish Date: May 11, 2025
Intervention Type: Other, Genetic
A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
Enrollment Status: Completed
Publish Date: April 18, 2025
Intervention Type: Behavioral, Other, Biological
Study Drug: Recombinant EphB4-HSA Fusion Protein
Study Phase: Phase 2
A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons
A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
Intervention Type: Procedure
Study Phase: Phase 2
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drugs: Apilimod, Rituximab, Atezolizumab
Study Phase: Phase 1
ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study
ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug, Device, Other
Study Drugs: Imiquimod, 5-Fluorouracil
Study Phase: Phase 3
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies
Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies
Enrollment Status: Terminated
Publish Date: March 16, 2023
Intervention Type: Other, Genetic
Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection
Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug, Other
Study Drug: Cabozantinib S-malate
Study Phase: Phase 1
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
Study Phase: Phase 4
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Terminated
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 16 Less Clinical Trials

73 Total Publications

Prognosis and Treatment of Plasmablastic Lymphoma in the United States: A Multicenter Retrospective Study.
Prognosis and Treatment of Plasmablastic Lymphoma in the United States: A Multicenter Retrospective Study.
Journal: Research square
Published: November 19, 2025
View All 73 Publications
Similar Doctors
Experienced in IgG4-Related Disease
Dr. Prakash D. Vishnu
Hematology Oncology | Hematology | Oncology
Experienced in IgG4-Related Disease
Dr. Prakash D. Vishnu
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (1.1 miles away)
206-288-1000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Prakash Vishnu is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Vishnu is rated as a Distinguished provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Splenectomy, and Bone Marrow Aspiration. Dr. Vishnu is currently accepting new patients.

Manoj Agarwal
Experienced in IgG4-Related Disease
Dr. Manoj Agarwal
Oncology | Hematology
Experienced in IgG4-Related Disease
Dr. Manoj Agarwal
Oncology | Hematology

Franciscan Oncology Associates At St. Anne

16233 Sylvester Road SW, Suite 110, 
Burien, WA 
 (11.0 miles away)
206-901-8901
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Manoj Agarwal, MD, is a board-certified medical oncologist. He works in partnership with patients to fight their cancer. The primary interest and focus of Dr. Agarwal’s professional activities has been the treatment and clinical research of lung cancer. As an active participant of the medical research community, he was involved with South West Oncology Group (SWOG) and other national cooperative groups. He has served as a primary investigator and research assistant on many trials over the past eight years. Now, he brings that experience and expertise to the community setting at St. Anne Cancer Center.Dr. Agarwal is a member of the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), American College of Physician Executives (ACPE) and International Association for Study of Lung Cancer (IASLC).Away from work, Dr. Agarwal enjoys traveling, with a goal to visit 150 countries in his lifetime. Dr. Agarwal is rated as an Advanced provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Essential Thrombocythemia, Autoimmune Hemolytic Anemia, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Schnitzler Syndrome.

Experienced in IgG4-Related Disease
Dr. Ndegwa M. Njuguna
Oncology
Experienced in IgG4-Related Disease
Dr. Ndegwa M. Njuguna
Oncology

Northwest Medical Specialties - Bonney Lake

10004 204th Avenue E, Suite 3400, 
Bonney Lake, WA 
 (30.8 miles away)
253-428-8700
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ndegwa Njuguna is an Oncologist in Bonney Lake, Washington. Dr. Njuguna is rated as a Distinguished provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Dehydration, Chronic B-Cell Leukemia (CBCL), Pleuropulmonary Blastoma, and Acute Mountain Sickness. Dr. Njuguna is currently accepting new patients.

VIEW MORE IGG4-RELATED DISEASE DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Aboulafia's expertise for a condition
ConditionClose
  • Elite
  • Anal Cancer
    Dr. Aboulafia is
    Elite
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Non-Hodgkin Lymphoma
    Dr. Aboulafia is
    Elite
    . Learn about Non-Hodgkin Lymphoma.
    See more Non-Hodgkin Lymphoma experts
  • Distinguished
  • Anemia
    Dr. Aboulafia is
    Distinguished
    . Learn about Anemia.
    See more Anemia experts
  • B-Cell Lymphoma
    Dr. Aboulafia is
    Distinguished
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Chronic B-Cell Leukemia (CBCL)
    Dr. Aboulafia is
    Distinguished
    . Learn about Chronic B-Cell Leukemia (CBCL).
    See more Chronic B-Cell Leukemia (CBCL) experts
  • Chronic Lymphocytic Leukemia (CLL)
    Dr. Aboulafia is
    Distinguished
    . Learn about Chronic Lymphocytic Leukemia (CLL).
    See more Chronic Lymphocytic Leukemia (CLL) experts
  • Diffuse Large B-Cell Lymphoma (DLBCL)
    Dr. Aboulafia is
    Distinguished
    . Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
    See more Diffuse Large B-Cell Lymphoma (DLBCL) experts
  • Essential Thrombocythemia
    Dr. Aboulafia is
    Distinguished
    . Learn about Essential Thrombocythemia.
    See more Essential Thrombocythemia experts
View All 10 Distinguished Conditions
  • Advanced
  • Acute Mountain Sickness
    Dr. Aboulafia is
    Advanced
    . Learn about Acute Mountain Sickness.
    See more Acute Mountain Sickness experts
  • Antiphospholipid Syndrome
    Dr. Aboulafia is
    Advanced
    . Learn about Antiphospholipid Syndrome.
    See more Antiphospholipid Syndrome experts
  • Bone Tumor
    Dr. Aboulafia is
    Advanced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Chronic Myelomonocytic Leukemia (CMML)
    Dr. Aboulafia is
    Advanced
    . Learn about Chronic Myelomonocytic Leukemia (CMML).
    See more Chronic Myelomonocytic Leukemia (CMML) experts
  • Cicatricial Pemphigoid
    Dr. Aboulafia is
    Advanced
    . Learn about Cicatricial Pemphigoid.
    See more Cicatricial Pemphigoid experts
  • Classical Hodgkin Lymphoma
    Dr. Aboulafia is
    Advanced
    . Learn about Classical Hodgkin Lymphoma.
    See more Classical Hodgkin Lymphoma experts
View All 33 Advanced Conditions
  • Experienced
  • Acinic Cell Carcinoma of Salivary Glands
    Dr. Aboulafia is
    Experienced
    . Learn about Acinic Cell Carcinoma of Salivary Glands.
    See more Acinic Cell Carcinoma of Salivary Glands experts
  • Acquired Hemophilia
    Dr. Aboulafia is
    Experienced
    . Learn about Acquired Hemophilia.
    See more Acquired Hemophilia experts
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Aboulafia is
    Experienced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Aboulafia is
    Experienced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Aboulafia is
    Experienced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Aboulafia is
    Experienced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
View All 126 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved